血清IL-6与脑出血后功能结局的相关性
本研究为FAST试验的探索性分析,纳入552例有入院血清IL-6水平的自发性脑出血患者。调整已知预后预测因素和治疗组后,入院IL-6每增加1 ng/L与90天不良功能结局(mRS 4-6)的OR为1.30(95%CI 1.04-1.63;P=0.02)。IL-6还与血肿体积和血肿周围水肿体积相关,且血肿体积关联受部位修饰。
要点
- 入院IL-6升高与脑出血后90天不良功能结局独立相关。
- IL-6与血肿体积的关联在脑叶出血中强于非脑叶出血。
- IL-6与血肿周围水肿体积独立相关。
核心结论
- 在FAST试验人群中,入院IL-6水平越高与90天功能结局越差、血肿体积和血肿周围水肿体积越大相关。
研究设计与样本
- 对重组活化凝血因子VII治疗急性脑出血的FAST试验进行探索性分析,纳入有入院血清IL-6水平的患者552例(占841例 enrolled 的66%),平均年龄64岁(SD 13),女性203例(37%)。
主要发现
- 调整已知脑出血预后预测因素和治疗组后,IL-6每增加1 ng/L与不良结局(改良Rankin量表4-6)的OR为1.30(95%CI 1.04-1.63;P=0.02)。
- 调整年龄、性别和血肿位置后,IL-6与血肿体积相关,且关联受位置修饰(多变量交互P=0.002),脑叶出血(β=12.51,95%CI 6.47-18.55;P<0.001)强于非脑叶出血(β=5.32,95%CI 3.36-7.28;P<0.001)。
- 调整年龄、性别、血肿体积和血肿位置后,IL-6与血肿周围水肿体积相关(β=1.22,95%CI 0.15-2.29;P=0.03)。
- 治疗组与IL-6水平或结局均无关联。
临床怎么用
- 入院血清IL-6可能有助于脑出血患者预后风险评估,但需进一步验证后才能用于临床决策。
局限性
- 本研究为FAST试验的探索性分析,仅66%的入组患者有入院IL-6数据。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: IL-6 (interleukin 6) is a proinflammatory cytokine and an established biomarker in acute brain injury. We sought to determine whether admission IL-6 levels are associated with severity and functional outcome after spontaneous intracerebral hemorrhage (ICH). METHODS: We performed an exploratory analysis of the recombinant activated FAST trial (Factor VII for Acute ICH). Patients with admission serum IL-6 levels were included. Regression analyses were used to assess the associations between IL-6 and 90-day modified Rankin Scale. In secondary analyses, we used linear regression to evaluate the association between IL-6 and baseline ICH and perihematomal edema volumes. RESULTS: Of 841 enrolled patients, we included 552 (66%) with available admission IL-6 levels (mean age 64 [SD 13], female sex 203 [37%]). IL-6 was associated with poor outcome (modified Rankin Scale, 4-6; per additional 1 ng/L, odds ratio, 1.30 [95% CI, 1.04-1.63]; P=0.02) after adjustment for known predictors of outcome after ICH and treatment group. IL-6 was associated with ICH volume after adjustment for age, sex, and ICH location, and this association was modified by location (multivariable interaction, P=0.002), with a stronger association seen in lobar (β, 12.51 [95% CI, 6.47-18.55], P<0.001) versus nonlobar (β 5.32 [95% CI, 3.36-7.28], P<0.001) location. IL-6 was associated with perihematomal edema volume after adjustment for age, sex, ICH volume, and ICH location (β 1.22 [95% CI, 0.15-2.29], P=0.03). Treatment group was not associated with IL-6 levels or outcome. CONCLUSIONS: In the FAST trial population, higher admission IL-6 levels were associated with worse 90-day functional outcome and larger ICH and perihematomal edema volumes.
引用
- Leasure AC, Kuohn LR, Vanent KN, et al. Association of Serum IL-6 (Interleukin 6) With Functional Outcome After Intracerebral Hemorrhage. Stroke. 2021. PMID: 33682454. doi:10.1161/STROKEAHA.120.032888
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。